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 Abstract  
Steroid minimization after kidney transplantation has become more widely practiced as 
transplant clinicians seek the potential benefits such as reduced cardiovascular risk 
factors, improved growth in pediatric patients, and improved compliance with the 
immunosuppression regimen. Steroid avoidance (i.e. no steroids after the first week) is 
generally favored compared to later withdrawal. Induction therapy is routine in this 
setting, frequently rabbit antithymocyte globulin (rATG, Thymoglobulin®) or off-license 
use of alemtuzumab. Direct comparisons of steroid minimization regimens versus 
standard steroid regimens are rare. However, the available data show that the risk of 
acute rejection is low when rATG or alemtuzumab induction is given to support steroid-
avoidance regimens after kidney transplantation. Steroid avoidance may be inadvisable 
in patients at high immunological risk or at risk of recurrent glomerular disease. Steroid 
withdrawal after day 8 may be possible without additional risk of rejection in patients 
given rATG induction, but while encouraging, the data are too sparse for firm 
conclusions. In summary, steroid avoidance may be beneficial for patients after renal 
transplantation, with the potential to avoid or reduce steroid-related comorbidities. Whilst 
depleting induction therapy could be the treatment of choice, results of prospective 
randomized, controlled studies are eagerly awaited. 
Keywords: induction, depleting, steroid sparing, avoidance, kidney transplantation, ATG, 
rabbit antithymocyte globulin, Thymoglobulin, alemtuzumab, Campath  
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Inducción con anticuerpos antilinfocitarios y minimización de esteroides en 
trasplante renal 
Abstract 
La minimizacion de esteroides después del trasplante renal constituye una práctica muy 
extendida, en la busqueda de potenciales beneficios cardiovasculares, mejor 
crecimiento en pacientes pediátricos o aumento de la adherencia al tratamiento 
inmunosupresor. El uso de inducción depletiva con ATG de conejo o alemtuzumab 
puede contribuir a evitar el uso de esteroides o al menos permitir su suspensión precoz. 
Esta estrategia se ha revisado en la literatura, añadiendo la opinión de expertos al 
análisis. La suspensión de esteroides muy precoz (antes de la primera semana) parece 
preferirse a la suspensión más tardía. En ese contexto, la inducción preventiva es la 
práctica más utilizada, habitualmente con globulina antitimocítica de conejo (rATG, 
Tymoglobulin) o alemtuzumab (en uso fuera de indicación). Son raras las 
comparaciones directas de los regímenes de minimización de esteroides con los de uso 
estándar. Sin embargo, los datos disponibles muestran que el riesgo de rechazo agudo 
es bajo cuando se administra rATG o alemtuzumab para facilitar la suspensión muy 
precoz de esteroides. Esta práctica puede ser menos aconsejable en pacientes con alto 
riesgo inmunológico o predispuestos a una recurrencia de la enfermedad glomerular de 
base. La suspensión de esteroides a partir del día 8 es factible sin que el riesgo de 
rechazo aumente en pacientes tratados con rATG. No obstante, y aunque los datos 
disponibles así lo sugieren, requieren confirmación definitiva. En conclusión, la 
minimización extrema de esteroides puede ser beneficiosa en pacientes que reciben un 
trasplante renal, con la ventaja que supone evitar o reducir la comorbilidad asociada con 
ese trtamiento. Si bien la inducción depletiva podría ser el tratamiento de elección en 
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ese contexto, son necesarios nuevos ensayos aleatorizados controlados que lo 
confirmen. 
Palabras clave: inducción, depleción, ahorro de esteroides, suspensión de esteroides, 
trasplante renal, ATG, glomulina antitimocítica de conejo, Timoglobulina, alemtuzumab 
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1. Introduction 
Steroid-sparing immunosuppressive regimens are widely used after kidney 
transplantation as clinicians seek to minimize steroid-related adverse events1. Rapid 
steroid discontinuation lowers the rates of cataracts, vascular necrosis and 
cytomegalovirus infection2 and may improve growth in children3. Cardiovascular benefits 
are less well established, although positive effects have been observed for lipid profile 
and weight gain4,5. Generally, it is difficult to demonstrate differences in randomized trials 
in unselected populations, and studies of steroid minimization regimens have often not 
reported steroid-related side effects, or were underpowered to demonstrate a significant 
difference. However, even if data remain unconvincing about reduced cardiovascular 
risk, the non-cardiovascular side effects of chronic steroid therapy require costly 
management6 and some, such as weight gain, can adversely affect patient compliance7,8 
with potential consequences for graft outcomes.  
Strategies for steroid minimization comprise either ‘steroid avoidance’ (or ‘steroid-free’) 
regimens, which will be defined here as no intravenous (i.v.) or oral steroids after the first 
1–2 weeks post-transplant, or steroid withdrawal i.e. steroid discontinuation after weeks 
1–24,9,10.  
Steroid avoidance protocols have become increasingly popular in recent years. Steroid-
free immunosuppression without induction therapy has been attempted after kidney 
transplantation using a calcineurin inhibitor (CNI)-based maintenance regimen, but 
randomized trials showed acute rejection to be significantly more frequent4,11,12 or more 
severe13 than with standard steroids. A series of randomized trials comparing steroid 
avoidance versus ongoing steroid therapy in selected populations receiving interleukin-2 
receptor (IL-2R) induction have reported mixed results14–18. High rates of biopsy-proven 
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acute rejection (BPAR) were observed in the FREEDOM study for patients given 
basiliximab induction with cyclosporine (CsA), mycophenolic acid (MPA) and either a 
single i.v. dose of steroids (31.5% BPAR at 1 year) or steroids to day 7 (26.1%)19. Other 
researchers have found no significant effect on BPAR using steroid avoidance with IL-
2R antagonist induction, especially with concomitant tacrolimus15,16, although BPAR may 
occur earlier16.  
Many centers, particularly in the US, instead employ lymphocyte-depleting induction 
when steroid-free therapy is planned, an approach that may be partly based on 
experience from conventional immunosuppressive regimens. Randomized trials of 
patients at low or moderate immunological risk given standard steroids have shown 
comparable rejection rates using induction with an IL-2R antagonist or rabbit 
antithymocyte globulin (rATG)19–22, but for high-immunologic risk populations both the 
overall rejection rate and the incidence of steroid-resistant rejection is lower with 
rATG23,24. This may have encouraged more frequent selection of rATG or another 
depleting agent when attempting steroid avoidance: almost 90% of kidney 
transplantation patients who are discharged on a steroid-free regimen in the US receive 
a lymphocyte-depleting induction agent25, with the remaining 10% given IL-2R 
antagonist induction.  
Steroid withdrawal after the first week post-transplant tends to be regarded with more 
caution. A meta-analysis of eight randomized trials found that steroid withdrawal after 
week 1 significantly increased both acute rejection and graft loss26. In a further meta-
analysis, in which only those trials that included CNI therapy with mycophenolate mofetil 
(MMF) were analyzed, graft loss was minimized, but the risk of acute rejection was still 
higher following steroid withdrawal27. The Kidney Disease: Improving Global Outcomes 
(KDIGO) recommendations suggest that in low-risk patients given induction therapy, 
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steroids can be discontinued during week 128. If steroids are administered beyond the 
first week post-transplant, however, KDIGO suggests that they be maintained 
thereafter28. This may, however, be an oversimplification. A recent Cochrane systematic 
review concluded that although late (month 3–6) steroid withdrawal is associated with 
increased rejection rates in CsA-treated patients (risk ratio 1.61, p=0.0018), this does not 
appear to be the case when tacrolimus is given with MMF (risk ratio 0.82, p=0.29)9,10,29,30. 
Equally, the safety of steroid withdrawal may be affected by the choice of induction 
therapy.  
This article reviews the evidence relating to lymphocyte-depleting induction with rATG or 
alemtuzumab to support steroid avoidance or withdrawal in kidney transplant recipients. 
It should be borne in mind that alemtuzumab in solid organ transplantation is used off-
label, and the indication is not likely to be forthcoming.   
2. Lymphocyte-depleting induction & steroid-free immunosuppression  
2.1 rATG induction 
Randomized trials relating to steroid-free treatment of kidney transplant patients given 
rATG induction are relatively rare, with only sparse data directly comparing steroid-free 
therapy versus standard steroids (Table 1). One may deduce, however, that steroid-free 
immunosuppression is safe, as shown in trials such as the one published in 2005 by 
Kandaswamy et al31. In that study, 239 first or second kidney transplant recipients all 
received rATG (1.25–1.5 mg/kg for five doses) with a single dose of i.v. steroids then 
oral steroids to day 531. The trial did not compare steroid-free with steroid conventional 
therapy: instead, all patients received the very short five-day steroid regimen. They were 
randomized to one of three maintenance regimens: CsA with MMF, high tacrolimus 
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(trough level 8–12 ng/mL) with low sirolimus (3–7 ng/mL), or low tacrolimus (3–7 ng/mL) 
with high sirolimus (8–12 ng/mL), and followed to month 24. Rates of BPAR were low 
and similar in all groups (4–6%); graft and patient survival was also excellent (Table 1). 
At month 24, 75%, 90% and 83% of patients, respectively, remained steroid-free, and 
the incidence of steroid-related events (post-lymphoproliferative disease, new-onset 
diabetes mellitus [NODAT], osteonecrosis and viral infection) was encouragingly low. 
There were no major differences in complications between groups, other than a higher 
rate of wound healing complications in the high sirolimus arm (p=0.02)31. These results 
suggest that any of these steroid-free maintenance protocols is effective when given with 
rATG induction, even in an unselected cohort of patients.  
One randomized trial that compared rATG induction with or without ongoing steroids was 
a 12-month single-center study in 60 first or second kidney transplant recipients32. In fact, 
what made this trial unique is that it compared steroid-free versus standard steroids as 
the single variation between the comparative arms. The rATG dose was 1 mg/kg, for 
three to five doses, with a seven-day course of i.v. steroids. Patients received tacrolimus 
with MMF, with or without oral steroids. Graft function and rates of clinical rejection (13% 
versus 11% in controls) were unaffected by the absence of steroid therapy. Protocol 
biopsies were undertaken in 19 patients at month 12, and although subclinical rejection 
rates were similar in both arms, the increase in fibrosis at 6 and especially at 12 months 
was significantly greater in the steroid-avoidance group (p<0.001), a potential cause for 
concern although in most patients fibrosis was mild (grade 1). Assessment of subclinical 
changes by protocol biopsies may be an important focus in future studies of steroid 
avoidance.  
Woodle et al undertook a multicenter, randomized trial in which 151 living-donor kidney 
transplant patients were given either rATG (1.25–1.5 mg/kg for four days) with steroids 
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discontinued by day 6, or to no induction with standard i.v. and oral steroids until at least 
month 3 post-transplant5. All patients were given tacrolimus and MMF, and dosing was 
similar in both treatment groups. By month 12, 72% of rATG-treated patients remained 
steroid-free, while in the control arm only 12% of patients managed to stop steroids. The 
12-month incidence of BPAR was 13.9% versus 19.4% for the rATG/steroid-free group 
versus the control arm (n.s.) (Figure 1). In terms of steroid-related adverse events, levels 
of total cholesterol was significantly lower in the steroid-free group at 12 months post-
transplant, with a trend to less weight gain (p=0.07)5.  
Other randomized trials have employed different rATG regimens with various 
maintenance protocols33–35. Each of these has shown good graft and patient survival 
rates, with no indication of increased rejection when steroid avoidance is supported by 
rATG induction (Table 1).  
Whether early steroid withdrawal after rATG induction could lead to an increased risk of 
donor-specific antibody (DSA) development was first studied by Delgado et al41 in low-
immunologic risk kidney transplant recipients. In this longitudinal study, performed in 37 
patients randomized to early corticosteroid withdrawal at day 7 post-transplant (n=21 
patients), or to maintenance steroid therapy (n=16) – with all patients receiving rATG 
induction – there was no difference between the two groups in terms of DSA 
development during five years' follow-up. Interestingly, only one patient developed DSA 
(in the control group). This is fewer than would be expected, suggesting a protective role 
for rATG in DSA occurrence. Supportive data were recently published in a study by 
Brokhof et al42 undertaken in a population of 114 consecutive moderately sensitized 
recipients who were divided into two groups based on induction immunosuppression 
(rATG versus basiliximab). At month 36 post-transplant, there was a lower incidence of 
de novo DSA and antibody-mediated rejection in the rATG group when compared with 
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basiliximab. However, in this study standard maintenance steroids were given to all 
patients.  
2.2 Alemtuzumab induction 
Several randomized trials of steroid-free therapy have employed alemtuzumab induction, 
at a dose of 30 mg given either once or twice (Table 1). Vathsala and colleagues 
performed a small, six-month study in which 30 patients were randomized to 
alemtuzumab with reduced-exposure CsA monotherapy and no oral steroids or to no 
induction with a conventional CsA-based regimen with steroids and azathioprine36. Graft 
survival was 85% at month 6 in the alemtuzumab group versus 100% in the control arm, 
but larger studies of alemtuzumab with reduced-CNI37, delayed CNI37 or tacrolimus 
monotherapy38,39 have not shown any deleterious effect on graft survival when 
alemtuzumab has been used to support steroid avoidance (Table 1). Consistently, the 
incidence of BPAR at 12 months post-transplant has been lower with alemtuzumab 
induction, a reduced-intensity maintenance regimen and a steroid-free protocol versus 
conventional regimens with36,37,40 or without38,39 steroids.     
The largest trial in this series is the 3C study40. A total of 852 patients were randomized 
to alemtuzumab (30 mg peri-operatively and on the subsequent day) with low-exposure 
tacrolimus (5–7 ng/mL) and reduced-dose MPA (enteric-coated mycophenolic acid 360 
mg b.i.d.), or to a conventional regimen of basiliximab induction, tacrolimus (5–12 
ng/mL), standard MPA dosing (540–720 mg b.i.d.) with ongoing oral steroids. During the 
first six months post-transplant, the risk of BPAR was significantly lower in the 
alemtuzumab group versus controls (Figure 2). The difference arose during the early 
weeks after transplantation and was accounted for by a reduced rate of T-cell mediated 
rejection (hazard ratio [HR] 0.37; 95% confidence interval [CI] 0.23–0.58; p<0.0001); 
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antibody-mediated rejection was similar in both treatment arms (HR 1.59; 95% CI 0.52–
4.86; p=0.41)40. Graft and patient survival rates at month 6 were similar between groups. 
Leukopenia was significantly more frequent under alemtuzumab, as would be expected, 
but there was no between-group difference in opportunistic infections or serious 
infections. Longer-term follow-up from this trial will be of interest, since at month 6 
patients were randomized to remain on tacrolimus or switch to sirolimus. Reconstitution 
of the lymphocyte population after recovery from alemtuzumab-induced depletion may 
on one hand have profound effects on the risk of graft rejection, or on the other hand 
may give rise to more tolerogenic lymphocyte subsets. One recent retrospective study of 
200 consecutive non-sensitized kidney transplant patients treated with rapid steroid 
taper reported that as well as higher rates of acute rejection, three-year graft survival 
was lower under alemtuzumab induction versus rATG43.  
No randomized trial of alemtuzumab with steroid avoidance after kidney transplantation 
has shown reduced patient survival when followed for up to two years36–40, an important 
point in view of the severe lymphocyte depletion associated with alemtuzumab and the 
potential risk for infectious deaths or malignancy.  
2. 3 Comparative studies between induction agents within steroid-free regimens 
Two registry analyses have specifically assessed outcomes according to type of 
induction in kidney transplant patients discharged on a steroid-free regimen25,44. 
Sureshkumar and colleagues analyzed Organ Transplantation and Procurement 
Network (OPTN) data from 9,172 patients who received a deceased-donor kidney 
transplant during 2000–2008, with a median follow-up of 26.8 months25. The risk of graft 
failure after adjustment for a range of potentially confounding variables was found to be 
significantly higher with alemtuzumab or IL-2R antagonist induction compared to rATG 
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(Figure 3). Further analyses showed that higher graft survival for rATG versus 
alemtuzumab was maintained in at-risk populations (sensitized patients [PRA >20%], 
expanded criteria donor recipients and cold ischemia time >24 hours)23 but significance 
was lost in these subpopulations for the comparison between rATG and IL-2R 
antagonists. Data on rejection were not reported, so it is unclear whether differences in 
graft failure were related to a lower propensity to rejection under rATG or other causes of 
graft loss. In a more recent cohort (2000 to 2012) of patients registered with OPTN, 
Tanriover et al analyzed lower-risk living-donor recipients of a first transplant who were 
discharged on tacrolimus and MMF, with or without steroid therapy44. Propensity scoring 
was used to address the risk of selection bias. Within the subpopulation that was 
discharged steroid-free (n=10,157), acute rejection at one year post-transplant was 
significantly lower with either rATG (odds ratio 0.73; 95% CI 0.59–0.90) or alemtuzumab 
(0.53; 0.42–0.67) versus IL-2R antagonist induction. The one-year risk of graft failure 
was higher with alemtuzumab versus IL-2R antagonist induction (odds ratio 1.27; 95% 
CI 1.03–1.56) but similar for rATG versus IL-2RA antagonists (1.19; 0.97–1.45).  
Randomized trials comparing steroid avoidance with different induction regimens are 
relatively rare (Table 2). In a double-blind, placebo-controlled trial of steroid cessation at 
seven days versus ongoing steroids, both with tacrolimus and MMF, the 191 patients in 
the steroid-withdrawal group received either rATG (n=125) or an IL-2R antagonist 
induction (n=66)46. In this subpopulation, the five-year incidence of BPAR was 14.4% 
versus 24.2%, respectively (p=0.09). Results of the ongoing SAILOR study, comparing 
rATG with steroid avoidance versus IL-2R antagonist induction with standard oral 
steroids in patients receiving low-dose tacrolimus and concentration-controlled MMF50, 
will help to clarify the relative effectiveness of each class of agent in preventing rejection 
in the absence of steroids. 
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In a large trial of kidney transplant patients stratified as either high or low immunological 
risk, Hanaway and colleagues randomized a 139 high-risk cohort to alemtuzumab or 
rATG, and 335 low-risk patients to alemtuzumab or basiliximab, all with tacrolimus and 
MMF; steroids were discontinued by day 546. In the high-risk group, there was no 
difference in the rate of BPAR between alemtuzumab and rATG at year 3 (Table 2). For 
low-risk patients, however, alemtuzumab induction was associated with a reduced rate 
of BPAR versus basiliximab (10% versus 22%, p<0.001). A further comparison of 
alemtuzumab versus rATG will be provided by the BEST study, an ongoing randomized, 
open-label trial in which patients receive belatacept-based immunosuppression with 
MPA and early steroid withdrawal, using induction with alemtuzumab in one group and 
rATG in a second group, or tacrolimus, MPA, early steroid withdrawal and rATG 
induction (NCT 01729494). 
Ciancio et al undertook a randomized, single-center study of combined induction 
protocols in 200 first kidney transplant patients, whereby rATG was combined with either 
daclizumab or with a single dose of alemtuzumab47 (Table 2). All patients were given 
oral steroids to day 7, with maintenance therapy comprising tacrolimus and MPA. As 
might be expected with this relatively intensive regimen, rates of BPAR were low in both 
groups (10% and 9%), although graft survival was numerically higher in the 
rATG/daclizumab arm (91% versus 83%, n.s.). Early leukopenia was more frequent than 
with rATG/alemtuzumab induction, despite reduced MPA dosing, than with 
rATG/daclizumab (12% versus 31%, p=0.002)47. Other comparative studies of rATG 
versus alemtuzumab or an IL-2R antagonist using steroid-avoidance regimens have 
usually been relatively small (<40 patients), with different maintenance protocols and 
steroid use between treatment arms, limiting interpretation48,49 (Table 2). One notable 
point was a high rate of BPAR (21.4% at month 12) in a small series of kidney-pancreas 
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patients randomized to alemtuzumab with tacrolimus monotherapy and no oral steroids48, 
but confirmatory data are lacking.  
Three randomized trials of alemtuzumab with steroid avoidance have used an IL-2R 
antagonist in the control arm, as discussed above, but since the maintenance regimen 
differed between groups the effect of the induction regimen cannot be assessed38–40.  
3. Lymphocyte-depleting induction and steroid withdrawal   
So far, head-to-head comparisons of steroid withdrawal with or without lymphocyte-
depleting induction therapy have not been undertaken. Typically, studies of steroid 
withdrawal either before or after the first year post-transplant have not included induction 
therapy4,9,10.  
One large study of late (month 3) steroid withdrawal allowed lymphocyte-depleting 
induction according to local practice. A third of patients (34% and 33% in the steroid-
withdrawal and control groups, respectively) received induction, but this included both 
rATG and monomurab (OKT3)51. In this subgroup of 169 patients, the 12-month 
incidence of BPAR was 14% without steroids compared to 17% in the steroids group i.e. 
steroid withdrawal was successfully achieved. In contrast, for the 331 patients without 
any induction therapy, BPAR was higher in the steroid-withdrawal patients (29% versus 
15% in controls). Although only a subanalysis, these data suggest an advantage for 
lymphocyte depleting induction when undertaking steroid withdrawal after kidney 
transplantation.  
In the SPIESSER study, 150 moderate-risk or low-risk kidney transplant patients 
underwent steroid withdrawal at the end of month 5 post-transplant49. All patients 
received rATG induction52. The intervention group was randomized to sirolimus and 
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MMF in a CNI-free regimen, while the control group received CsA and MMF. In both 
arms, the 12-month incidence of BPAR was low (14% with sirolimus/MMF, 9% with 
CsA/MMF) and more than 80% of patients remained steroid-free at month 12. Steroid 
withdrawal around month 6 thus appears feasible under rATG induction with or without 
CNI therapy, when high-risk patients are excluded.  
4. High-immunological risk patients 
Steroid-free immunosuppression is less frequently attempted in high-risk patients, and 
data are limited (Table 3). Two retrospective single-center studies in African-American 
populations have assessed outcomes following rATG induction with i.v. steroids to day 4, 
both with a maintenance regimen of tacrolimus combined with either sirolimus or 
MMF43,53. The one-year rates of BPAR in both series were acceptable for this high-risk 
group (13–14%), and graft and patient survival was excellent, but firm conclusions 
cannot be drawn in the absence of prospective trials. One small randomized trial (n=21) 
selectively recruited high-immunological risk patients (panel reactive antibodies [PRA] 
>20% or repeat transplantation)55. The treatment regimens comprised alemtuzumab (a 
single dose of 30 mg) with tacrolimus and no steroids, or rATG (total dose 6 mg/kg) with 
tacrolimus, MMF, and steroids to day 5.  In this small series, the rate of BPAR at a 
median of 12.4 months was 18.2% with alemtuzumab and 37.5% with rATG, while graft 
survival rates were 85.7% and 87.5%, respectively55. These relatively high rates of 
rejection suggest that steroid avoidance may not be a favorable option in high-risk 
individuals unless there is a specific clinical imperative. None of these studies employed 
Luminex® technology to define the immunological risk pre-transplant, however, which 
makes any conclusion uncertain.   
5. Steroid minimization and risk of recurrence of glomerular diseases 
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The advantages of steroid avoidance also have to be balanced against the risk of 
recurrence of certain glomerulopathies. In particular, several retrospective studies have 
shown that recurrence of IgA nephropathy is reduced in the presence of long-term 
steroid therapy. Among them, Clayton et al58 analyzed data from the Australia and New 
Zealand Dialysis and Transplant Registry (ANZDATA) from 1,521 adult recipients of a 
ﬁrst kidney transplant in whom kidney failure was due to biopsy-proven IgA nephropathy. 
After adjustment for various confounding variables, steroid use was strongly associated 
with a reduced risk of IgA nephropathy recurrence (HR 0.50, 95% CI 0.30–0.84). Only 
9% of patients in the study population received depleting induction therapy. Kukla et al 
observed that steroid avoidance may be associated with a higher rate of recurrent 
glomerulopathy but found no apparent increase in the risk of graft loss in patients treated 
with rATG induction coupled with maintenance therapy comprising tacrolimus and an 
antimetabolite59. Von Visger and colleagues60 recently showed similar results in a cohort 
of 124 patients, in which 91% of patients in the steroid-free group received lymphocyte-
depleting induction. Although the mechanisms involved have not been elucidated, 
steroid avoidance would not appear advisable in kidney transplant patients in whom 
kidney failure was caused by IgA nephropathy. 
In other types of glomerular diseases with risk of recurrence, such as focal segmental 
glomerulosclerosis, membranoproliferative glomerulonephritis or lupus nephritis, for 
which steroids are used as part of the treatment strategy in native kidneys, some centers 
tend to maintain steroids in the immunosuppressive protocol after transplantation even in 
the absence of relevant studies.  
6. Steroid minimization in pediatric patients 
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Steroid-sparing strategies are of particular interest in children. Randomized trials of 
steroid avoidance in pediatric populations under lymphocyte-depleting induction have 
not, however, been carried out to date. In a single-center prospective study, Chavers et 
al used rATG induction at a relatively high dose (1.5 mg/kg for between five and seven 
doses) with i.v. steroids to day 5, with CsA and MMF as maintenance therapy3 (Table 3). 
The rate of BPAR (19% at two years) was acceptable and, importantly, children given 
the rATG/steroid-free regimen showed significantly improved growth compared to 
matched controls given oral steroid therapy (mean standard height deviation score -0.9 
versus -1.9 in controls; p=0.003). Other steroid-related effects (body mass index, lipid 
profile, blood pressure) were unaffected although leukopenia was reduced (p=0.02) and 
there were fewer Epstein-Barr infections in the steroid-free arm (p=0.04)3. Li et al, in a 
single-center retrospective study, achieved a 0% rate of BPAR at a mean of 13 months 
post-transplant when a relatively high dose of rATG was employed (total dose 9 mg/kg) 
with no oral steroids, tacrolimus and MMF, but growth data were not reported and there 
was no comparison versus a steroid-treated cohort. Lastly, a retrospective single-center 
study by Wittenhagen et al has described a low rate of BPAR (9% at one year) in 
children given lymphocyte-depleting induction (primarily rATG) with different 
maintenance regimens57. Use of depleting induction in a steroid-avoidance regimen 
using standard maintenance therapy seems adequate to prevent rejection in children 
following kidney transplantation, and merits a more rigorous examination.  
7. Steroid- and CNI-avoidance regimens 
A small number of trials have investigated novel immunosuppressive regimens that 
avoid both steroids and CNI therapy61–63. Ferguson and colleagues randomized 89 
kidney transplant recipients at low or moderate immunological risk to one of three 
groups: the costimulation blocker belatacept with MMF, belatacept with sirolimus, or 
 19 
tacrolimus with MMF62. All patients received rATG induction (total dose 6 mg/kg) with i.v. 
steroids to day 4 post-transplant and no oral steroids. At one year, rates of BPAR were 
acceptable with belatacept and MMF (14%), but lower and similar in the 
belatacept/sirolimus group (4%) and the control arm (3%). More patients in the 
conventional tacrolimus/MMF group remained steroid-free at month 12, however (93% 
versus 73% or 77% in the belatacept group). So while promising, a CNI-free strategy 
may not be optimal for achieving steroid-free immunosuppression even with lymphocyte-
depleting induction. Other small trials have also pointed to low or acceptable rates of 
BPAR when alemtuzumab induction is used to support CNI-free and steroid-free 
therapy61,,63, one of which achieved highly minimized immunosuppression by giving bone 
marrow infusions63, but such regimens are not currently used in routine practice.   
8. Discussion 
The literature contains few direct comparisons of steroid minimization regimens versus 
conventional steroid treatment in kidney transplant patients receiving lymphocyte-
depleting induction. Studies are typically relatively small, with limited follow-up periods, 
and to date, the occurrence of de novo antibodies and antibody-mediated rejection is 
undocumented. Nevertheless, the available data show that the risk of acute rejection is 
low when rATG induction is given to support steroid-free regimens after kidney 
transplantation, at least for the first one to two years post-transplant. In the US, it is 
common practice to use rATG and stop steroids by day 7, and this appears to be a 
reasonable approach that does not increase the risk of rejection. In contrast, rejection 
may be more likely under IL-2R antagonist induction using a steroid-avoidance regimen. 
Induction with alemtuzumab appears effective in supporting steroid-free 
immunosuppression, although it is not licensed for use in solid organ transplant 
recipients. For patients at high immunological risk, the limited data available suggest that 
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steroid minimization may not be advisable even with depleting induction therapy. The 
availability of single-antigen bead technology, permitting more precise measurement of 
anti-HLA antibodies, may enable more accurate identification of high-risk individuals and 
feasibly, expand the pool of patients considered candidates for steroid minimization.   
In children, non-randomized studies indicate that depleting induction with standard 
maintenance therapy effectively prevents acute rejection with steroid avoidance, an 
encouraging finding given the growth inhibition associated with chronic steroid 
administration. More ambitious regimens have been attempted which include both 
steroid avoidance and CNI avoidance, of which depleting induction with maintenance 
therapy comprising belatacept and sirolimus appears the most promising, but currently 
can be regarded as an experimental approach.   
There is some suggestion that steroid-associated side effects such as dyslipidemia and 
weight gain are lower with steroid-free immunosuppression, but this has not been shown 
to translate to an improvement in hard clinical endpoints. Given the lack of strong 
evidence in this field, no strong conclusions can be made.  
Early steroid therapy with subsequent withdrawal (i.e. later than the first one or two 
weeks post-transplant) may be possible without additional risk of BPAR in patients who 
have received rATG induction, but while encouraging the data are too sparse for firm 
conclusions. Where late steroid withdrawal is attempted (months 3 to 6 post-transplant), 
it seems preferable to employ tacrolimus-based immunosuppression over CsA. Overall, 
the effectiveness of steroid avoidance regimens in this setting is better documented than 
subsequent withdrawal strategies.   
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In summary, there is a suggestion that steroid avoidance is beneficial for patients after 
renal transplantation, with the potential to avoid or reduce steroid-related comorbidities. 
Whilst the limited literature seems to indicate that depleting induction therapy could be 
the treatment of choice for steroid minimization and avoidance in kidney transplantation, 
the results of prospective randomized, controlled studies are eagerly awaited50.  
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Table 1. Randomized trials of rATG or alemtuzumab induction with steroid avoidance in kidney transplantation 
 
Study Risk status 
N 
 
Study 
duration 
rATG Steroids Maintenance BPAR 
(%) 
Graft/patient 
survival (%)
a
 
rATG induction 
Kandaswamy 2005
31
 
Single center  
Unselected 
N=239 
2Y 1.25-1.5 mg/kg x 5 i.v. + oral to day 5 CsA, MMF 6 95/98 
High TAC 
Low SRL 
4 94/97 
Low TAC 
High SRL 
5 96/97 
Laftavi 2005
32
 
Single center 
Moderate/low 
N=60 
12M 1 mg/kg x 3-5 i.v.+ oral to day 7 TAC, MMF 13 - 
i.v.+ oral ongoing 11 - 
Stevens 2008
33
 
Single center 
Moderate/low 
N=180 
6M 6 mg/kg x 1 i.v. only (< 7 days) TAC/SRL or 
MMF/SRL 
8 100/100 
 
1.5 mg x 4 12 98.6/96 
Ciancio 2008
34
 
Single center 
Unselected 
N=150 
12M 1 mg/kg x 3 + 
daclizumab 1 mg/kg 
x 2 
 i.v.+ oral (< 7 days) TAC, MMF 3 97/100 
TAC, EC-MPS 9 96/99 
Woodle 2010
5
 
Multicenter 
Living donor 
Moderate/low 
N=151 
12M 1.25-1.5 mg/kg x 4 i.v.+ oral (< 7 days) TAC, MMF 13.9 98.1/100 
No rATG i.v. + oral ≥ 3M 19.4 97.9/100 
Grafals 2014
35
 
Single center 
Low 
N=45 
12M 0.75 mg/kg x 3 i.v.+ oral (< 7 days) TAC, MMF 10 85/85 
1.24 mg/kg x 3 17 100/100 
Alemtuzumab induction 
Vathsala 2005
36
 
Multicenter 
Moderate/low  
N=30 
6M ALEM 20 mg x 2 i.v. x 1 Reduced CSA 25 85/95 
None Standard CSA, AZA 20 100/100 
Margreiter 2008
37
 
Multicenter 
Moderate/low  
N=131 
12M ALEM 20 mg x 2 i.v. x 2 Delayed TAC 20 96/98 
None Standard TAC, MMF 32 90/98 
Chan 2011
38
 
Single center 
Unselected 
N=123 
24M ALEM 30 mg x 1 i.v. + oral to day 7 TAC 11.1 97.6/100 
DAC 2 mg/kg x 3 TAC, MMF 17.7 95.1/97.5 
Welberry Smith 
2013
39
 
Single center 
Moderate/ 
low 
N=116 
12M ALEM 30 mg x 1 i.v. x 1 TAC 10.3 94.9/96.6 
BAS 20 mg x 2 TAC, MMF 24.1
b
 94.8/96.6 
 31 
3C Study Group 2014 
Multicenter
40
 
 
 
Unselected 
(4% 
sensitized) 
N=852 
6M ALEM 30 mg x 2 None Reduced TAC 
Reduced MMF 
7 96/97 
BAS 20 mg x 2 Oral (ongoing) TAC, MMF 16
c
 97/99 
ALEM, alemtuzumab; BAS, basiliximab; BPAR, biopsy-proven acute rejection; CsA, cyclosporine; DAC, daclizumab; EC-MPS, enteric-coated 
mycophenolate sodium; i.v., intravenous; MMF, mycophenolate mofetil; rATG, rabbit antithymocyte globulin; SRL, sirolimus; TAC, tacrolimus 
a
 At end of study (see Study duration in column 3) 
b
p=0.049 
c
p<0.0001 
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Table 2. Randomized comparative trials of induction therapy with steroid avoidance in kidney transplantation 
 
Study Risk status 
N 
 
Study 
duration 
Induction Steroids Maintenance BPAR 
(%) 
Graft/patient 
survival 
(%)
a
 
Woodle 2008
45
  
Multicenter 
Low or 
moderate 
N=191 
5Y rATG 1.5 mg/kg x 4 
 
i.v./oral to day 7 TAC 14.4 
 
- 
IL-2RA
b
 MMF 24.2 - 
Hanaway 
2011
46
 
High 
N=139 
3Y Alemtuzumab 30 mg 
x 1 
Steroids ≤5 days TAC 
MMF 
18 99 
rATG 1.5mg/kg x 4 15 91 
Low 
N=335 
Alemtuzumab 30 mg 
x 1 
10
c
 95 
BAS 20 mg x 2 22
c
 98 
Ciancio 2011
47
 
Single center 
Unselected 
N=200 
Median 
38M 
rATG 1 mg/kg x 3 + 
DAC 1 mg/kg x 2 
i.v. x 3 + oral (< 
day 7) 
Reduced TAC 
EC-MPS 
10 
 
 
91/96 
(4 years) 
rATG 1 mg/kg x 1 + 
ALEM 0.3 mg/kg x 1 
Reduced TAC 
50% EC-MPS 
9 83/92 
(4 years) 
Bösmüller 
2012
48
 
Single center 
Kidney-
pancreas 
N=30 
12M ALEM 30 mg  
x 1 
i.v. x 1 TAC 21.4 92.8/100 
rATG 4 mg/kg x 1 or 
ATG-F 8 mg/kg x 1 
i.v. x 2 
+ oral to month 3 
TAC, MMF 0 87.5/100 
Ciancio 2010
49
 
Single center 
Living donor 
N=38 
Median 
47M 
rATG 1 mg/kg x 7 i.v. x 3 + oral 
ongoing 
TAC 
MMF 
0 100/100 
ALEM 0.3 mg/kg x 2 i.v. x 2 + oral 
(≤day 7) 
TAC 
50% MMF 
7.7 92.3/92.3 
DAC 1 mg/kg x 5 i.v. x 3 + oral 
ongoing 
TAC 
MMF 
8.3 100/100 
 
* At end of study (see Study duration in column 3) 
b
 Basiliximab or daclizumab 
c
 p=0.003    ALEM, alemtuzumab; BAS, basiliximab; BPAR, biopsy-proven acute rejection; EC-MPS, enteric-coated mycophenolate sodium; IL-
2RA, interleukin 2 receptor antagonist; i.v., intravenous; MMF, mycophenolate mofetil; rATG, rabbit antithymocyte globulin; TAC, tacrolimus 
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Table 3. rATG or alemtuzumab induction with steroid avoidance in high-risk or pediatric kidney transplant populations 
 
Study Population 
N 
Study 
duration 
Induction Steroids Maintenance BPAR 
(%) 
Graft/patient 
survival (%)
a
 
High immunological risk  
Haririan 2006
53
 
Single center 
Retrospective 
Cohort study 
African-
American 
N=73 
12M rATG 1.5 mg/kg 
Mean 4.3 doses 
i.v. to  
day 4 
TAC or SRL, MMF 13 100/- 
rATG 1.5 mg/kg 
Mean 7.1 doses 
i.v. + oral 
ongoing 
15 97/- 
Zeng 2007
54
 
Single center 
Retrospective 
African-
American 
N=57 
12M rATG 1.5 mg/kg x 
4 
i.v. to  
day 4 
TAC or SRL, MMF 14 96/98 
Thomas 2008
55
 
Single center 
Randomized 
High risk
b
 
N=21 
Median 
12.4M 
Alemtuzumab 30 
mg x 1 
i.v. x 1 TAC 18.2 85.7/100 
(1 year) 
rATG 1.5 mg/kg x 
4 
i.v. + oral to day 
5 
TAC, MMF 37.5 87.5/87.5 
(1 year) 
Children        
Chavers 2009
3
 
Single center 
Prospective 
Matched controls 
Age 7.8-18 
N=60 
2Y rATG 1.5 mg/kg 
x 5-7  
i.v. to  
day 5 
CSA, MMF 19 86/95
c
 
rATG 1.5 mg/kg 
x 6-15 
Oral steroids 
ongoing 
CSA, AZA 31 90/97
c
 
Li 2010
56
 
Single center 
Retrospective 
control group 
rATG: High 
risk 
DAC: Low-risk 
Mean ~14Y 
N=26 
Mean 13M rATG 1.5 mg/kg x 
6 
i.v. to  
day 6 
TAC, MMF 0 100/- 
DAC to M6  None TAC, MMF 0 100/- 
Wittenhagen 
2014
57
 
Single center 
Retrospective 
Age 1.1-14.9Y 
N=65 
≤10Y ATG to 1999 
then rATG 1.25 
mg/kg 5-10 days 
None CSA to 1995, 
CSA/MMF to 2004, 
TAC/MMF to 2009 
9 (1 
year) 
71/93  
(10 years)
d
 
 
a
 At end of study (see Study duration in column 3) unless otherwise stated
 
b
 Panel reactive antibodies >20% or retransplantation 
c
 Significantly improved growth in steroid-free group (mean standard height deviation score -0.9 vs -1.9 [p=0.003]). Body mass index was similar in 
both groups 
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d
 Significantly improved growth after transplantation (mean standard height deviation score increased from -1.7 to -1.1 [p=0.007]). Body mass 
index remained stable 
AZA, azathioprine; BPAR, biopsy-proven acute rejection; CSA, cyclosporine; DAC, daclizumab; i.v., intravenous; MMF, mycophenolate mofetil; 
rATG, rabbit antithymocyte globulin; SRL, sirolimus; TAC, tacrolimus 
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Figure legends 
 
Figure 1. Freedom from biopsy-proven acute rejection (BPAR), in moderate- or low-risk 
living donor kidney transplant patients randomized to rabbit antithymocyte globulin 
(rATG) with intravenous steroids only, or to no steroids with intravenous steroids and 
oral steroids for ≥3 months, both with tacrolimus (TAC) and mycophenolate mofetil 
(MMF) (Kaplan-Meier estimates). No statistical analysis was provided (observed rates of 
BPAR: 13.9% for rATG/TAC/MMF versus 19.4% for TAC/MMF/steroids; p=NS). 
Reproduced with permission from5.   
 
Figure 2. Incidence of biopsy-proven acute rejection (BPAR) in 852 unselected kidney 
transplant patents randomized to alemtuzumab induction with low-exposure tacrolimus, 
low-dose mycophenolic acid and no steroids, or to basiliximab induction with standard 
tacrolimus, standard mycophenolic acid and standard steroids. HR, hazard ratio; CI, 
confidence interval. Reproduced with permission from40. 
 
Figure 3. Probability of graft survival after adjustment for prespecified donor, recipient 
and transplant-related variables in deceased-donor kidney transplants performed during 
2000–2008 registered with the Organ Procurement and Transplantation Network 
(OPTN) who were discharged on steroid-free immunosuppression. HR, hazard ratio; CI, 
confidence interval; rATG, rabbit antithymocyte globulin; IL-2R, interleukin-2 receptor. 
Reproduced with permission25.  
 
 
 
 
 
 
 
